Cancer Care Ontario | Cancer Care Ontario

lenvatinib - For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

lenvatinib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2020

Regimen

LETRPALB

Cancer Type:

Breast

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria

ODB - General Benefit

letrozole

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

palbociclib,

letrozole

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

LETRRIBO

Cancer Type:

Breast

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria

ODB - General Benefit

letrozole

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

letrozole,

ribociclib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

LENV

Cancer Type:

Genitourinary,

Renal cell / Kidney

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Drugs Used:

lenvatinib (Unfunded)

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2020

Guidelines and Advice

Locoregional Management of In-Transit Metastasis in Melanoma

Status: Current
ID: GL 8-10
Version: N/A

Feb 2020

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Mesothelioma (Pleural),

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

larotrectinib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2025

Drug